Bimekizumab Shows Efficacy in Psoriatic Arthritis With or …
WEB1 day ago · Patients with psoriatic arthritis (PsA) who received bimekizumab demonstrated sustained improvements in clinical outcomes for up to 52 weeks, with or without the use of concomitant methotrexate (MTX), according to study results published in ACR Open Rheumatology.. Researchers performed a post hoc analysis of data from the BE OPTIMAL (ClinicalTrials.gov Identifier: NCT03895203), BE COMPLETE ...
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab …
WEB2 days ago · Psoriatic arthritis (PsA) is a serious, highly heterogeneous, chronic, systemic inflammatory condition affecting both the joints and skin, with a prevalence of 0.02 percent to 0.25 percent of the ...
Bimekizumab Approved for Psoriatic Arthritis, Ankylosing …
WEB2 days ago · The FDA has approved bimekizumab-bkzx (BIMZELX) for treating active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS) in adults. 1 "In Phase 3 clinical studies, the clinically meaningful and consistent clinical response in patients who had a previous inadequate response to TNF ...
UCB Announces U.S. FDA Approvals for BIMZELX ... - Morningstar
WEB2 days ago · Psoriatic arthritis (PsA) is a serious, highly heterogeneous, chronic, systemic inflammatory condition affecting both the joints and skin, with a prevalence of 0.02 percent to 0.25 percent of the ...
FDA OKs Bimzelx for psoriatic arthritis, ankylosing ... - Healio
WEB1 day ago · The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according ...
New research explains mechanisms behind psoriatic arthritis
WEBJan 24, 2024 · New research shows how inflammatory proteins take the brakes off synovial cell growth in joints, leading to the abnormal tissue accumulation associated with psoriatic arthritis.
Psoriatic arthritis: New drug Bimzelx shows promise as treatment
WEBJan 29, 2024 · Psoriatic arthritis (PsA) is a common and difficult-to-treat condition that often occurs with psoriasis. The drug company UCB recently developed a new PsA treatment called Bimzelx. Bimzelx...
Two sides of management recommendations for psoriatic arthritis …
WEBMay 21, 2024 · Psoriatic arthritis (PsA) is a complex, chronic inflammatory and multidomain disease that can lead to disability and reduced quality of life 1. In the past 20 years, pharmacological and...
Overview of Latest Treatment Strategies for Active Psoriatic Arthritis ...
WEBKey Takeaways. The efficacy of bimekizumab in patient-reported outcomes, including pain and fatigue, in psoriatic arthritis (PsA), was supported in a pooled analysis of the BE COMPLETE and BE OPTIMAL trials. Another study presented at the meeting showed no increase in safety signals with long-term use of bimekizumab in PsA.
Psoriatic arthritis | Nature Reviews Disease Primers
WEBAug 12, 2021 · Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features that complicates skin or nail psoriasis in up to 30% of patients. No diagnostic criteria or...